AlloGen-LI ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 70 | Spinal stenosis | 1 |
70. Spinal stenosis
Clinical trials : 95 / Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02932020 (ClinicalTrials.gov) | October 2016 | 4/10/2016 | AlloGen-LI Treatment of Spinal Stenosis | Pilot Study Investigating the Utility of Epidural AlloGen-LI Injection for Treatment of Spinal Stenosis Symptoms | Low Back Pain | Drug: AlloGen-LI;Drug: depomedrol;Device: MRI;Drug: 0.5% marcaine | University of Southern California | Vivex Biomedical, Inc. | Withdrawn | 18 Years | N/A | All | 0 | N/A | United States |